Journal
CLINICAL CANCER RESEARCH
Volume 27, Issue 6, Pages 1604-1611Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-20-4084
Keywords
-
Categories
Funding
- NCI [UM1 CA186709]
- NCI-CTEP [UM1 CA 186709]
- Dana-Farber Cancer Institute-Brigham and Women's Hospital [UM1 CA 186709]
- NIH grant [NIH R35 - R35CA220497]
- Damon Runyon Cancer Research Foundation grant [CI-86-16]
- Expect Miracles Foundation
- Robert and Rene Belfer Foundation
Ask authors/readers for more resources
The study evaluated the safety and efficacy of combination therapy with osimertinib and navitoclax in advanced EGFR-mutant non-small cell lung cancer patients. Results demonstrated that the combination therapy was safe and effective at the recommended dose, with a high objective response rate of 100% in patients.
Purpose: Osimertinib is an effective therapy in EGFR-mutant non-small cell lung cancer (NSCLC), but resistance invariably develops. Navitoclax is an oral inhibitor of BCL-2/BCL-xL that has exhibited synergy with osimertinib in preclinical models of EGFR-mutant NSCLC. In hematologic malignancies, BCL-2 family inhibitors in combination therapy effectively increase cellular apoptosis and decrease drug resistance. Patients and Methods: This single-arm phase Ib study evaluated safety, tolerability, and feasibility of osimertinib and navitoclax, including dose expansion in T790M-positive patients at the recommended phase II dose (RP2D). Eligible patients had advanced EGFR-mutant NSCLC with prior tyrosine kinase inhibitor exposure. Five dose levels were planned with osimertinib from 40 to 80 mg orally daily and navitoclax from 150 to 325 mg orally daily. Results: A total of 27 patients were enrolled (18 in the dose-escalation cohort and nine in the dose-expansion cohort): median age 65, 67% female, 48% exon 19 del, and 37% L858R, median one prior line of therapy. The most common adverse events were lymphopenia ( 37%), fatigue (22%), nausea ( 22%), and thrombocytopenia (37%). No dose-limiting toxicities were seen in dose-escalation cohort; osimertinib 80 mg, navitoclax 150 mg was chosen as the RP2D. Most patients (78%) received >95% of planned doses through three cycles. In expansion cohort, objective response rate was 100% and median progression-free survival was 16.8 months. A proapoptotic effect from navitoclax was demonstrated by early-onset thrombocytopenia. Conclusions: Oral combination therapy with navitoclax and osimertinib was safe and feasible at RP2D with clinical efficacy. Early thrombocytopenia was common, supporting an target engagement by navitoclax. Further study of BCL-2/BCL-xL inhibition to enhance osimertinib activity is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available